The lead compound, named NVX-144, is part of Novelix’ pipeline of first-in-class small molecule targeted drugs for cancers resistant to standard treatment. Based on preclinical data, Novelix anticipates that NVX-144 will be the first product in its portfolio to enter clinical development in late 2006.
“NVX-144 is unique among anticancer drugs in that it potently induces the anticancer gene IL-24. This causes tumor cells to self-destruct, while sparing normal tissues. IL-24 is a compelling target for oncology drug development,” said Dr Burkhard Jansen, CEO and co-founder of Novelix.
Novelix’ chairman Dr Timothy Triche added that the compound showed evidence of the safety and efficacy characteristics needed for rapid clinical development.
Novelix Pharmaceuticals is a biotechnology company committed to developing first-in-class targeted small molecules for cancer therapy. The company has currently selected four compounds for development.